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Facioscapulohumeral muscular dystrophy (FSHD) is one of the most prevalent adult muscular dystrophies. The
common clinical signs usually appear during the second decade of life but when the first molecular dysregula-
tions occur is still unknown. Our aim was to determine whether molecular dysregulations can be identified
during FSHD fetal muscle development. We compared muscle biopsies derived from FSHD1 fetuses and the
cells derived from some of these biopsies with biopsies and cells derived from control fetuses. We mainly
focus on DUX4 isoform expression because the expression of DUX4 has been confirmed in both FSHD cells
and biopsies by several laboratories. We measured DUX4 isoform expression by using qRT-PCR in fetal
FSHD1 myotubes treated or not with an shRNA directed against DUX4 mRNA. We also analyzed DUX4 down-
stream target gene expression in myotubes and fetal or adult FSHD1 and control quadriceps biopsies. We
showthatbothDUX4-FL isoformsarealreadyexpressed inFSHD1myotubes. Interestingly,DUX4-FL expression
level is much lower in trapezius than in quadriceps myotubes, which is confirmed by the level of expression of
DUX4 downstream genes. We observed that TRIM43 and MBD3L2 are already overexpressed in FSHD1 fetal
quadriceps biopsies, at similar levels to those observed in adult FSHD1 quadriceps biopsies. These results in-
dicate that molecular markers of the disease are already expressed during fetal life, thus opening a new field of
investigation for mechanisms leading to FSHD.
INTRODUCTION
Facioscapulohumeral muscular dystrophy (FSHD) is one of
the most frequent muscular dystrophies with an incidence of
4/100 000 (www.orpha.net, June 2013). The pathology often
begins during late adolescence with an asymmetric atrophy of
muscles located in the face, the shoulder and in the arms.
A high inter-individual variability is observed with very variable
phenotypes being reported for the same genotype (1,2). In
general, the pathology progresses slowly. The genetic cause of
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the disease was proposed 20 years ago (3): FSHD is classically
associated with the contraction of a macrosatellite repeat array
in the sub-telomeric region of chromosome 4q35 (for review
see (4)). This region normally consists of 11–100 tandem
repeats of a 3.3 kb D4Z4 unit, and deletions leaving only 1 to
10 D4Z4 repeats have been associated with FSHD1 patients.
In FSHD2 patients, the contraction of the D4Z4 array is not
observed although the clinical features are identical to those
observed in FSHD1 patients (5).
D4Z4 repeats are not restricted to chromosome 4, but FSHD1
has only been associated with D4Z4 contractions occurring
on chromosome 4. Moreover, a complex genomic context (for
review see (6)) is required for FSHD onset. Two allelic variants
of chromosome 4q (4qA and 4qB) exist in the region distal to
D4Z4 and FSHD seems to be almost always associated with
4qA (7–11), which contains a polyadenylation signal for tran-
scripts encoded from the D4Z4 unit (12). Each D4Z4 region con-
tains one open reading frame encoding the double homobox gene
DUX4 (13), but owing to the presence of the polyadenylation
signal located immediately after the D4Z4 repeats, only the
last D4Z4 unit is able to generate a stable mRNA (12,14). In
most of the cases, full-length DUX4 is expressed in FSHD
patients whereas it is not expressed in control individuals (15–
17). The expression of DUX4, always associated with the 4qA
variant, has introduced the notion of a permissive chromosome
for FSHD (12). Combined with the fact that at least one D4Z4
unit is required to develop FSHD (18), it has been proposed
that DUX4 may play a role in the development of the pathology,
although its role is still unclear. The pre-messenger RNA can
generate at least three different mRNAs varying in size (15).
The shortest one (DUX4-S) can be found in both control and
FSHD biopsies as well as in cell culture, whereas the largest
one (DUX4-FL) is mainly found in FSHD individuals (16,17).
The two DUX4-FL isoforms differ by the retention or not of
the first intron located in the 3′UTR. Overexpression of
DUX4-FL protein appears to be highly toxic (19–22), and its ex-
pression has been proposed to generate a disorganization of the
nuclear envelope (23), atrophic myotubes (20), an activation of
the PITX1 gene (14), but also of germline genes, retroelements
and immune mediators (24), and may cause a p53-dependent
myopathy in vivo (25). Interestingly, DUX4 expression has
also been described in FSHD2 patients (16) and these patients
also carry the 4qA haplotype (12).
In FSHD1, D4Z4 contraction has been associated with more
relax chromatin structure leading to the expression of DUX4.
FSHD2 patients do not have D4Z4 contraction but do also
reveal the more relax chromatin structure and subsequent
DUX4 expression. Recently, Lemmers et al. identified the
causal determinant for most FSHD2 patients and have clearly
demonstrated that mutations in the epigenetic modifier
SCHMD1 gene are a causal determinant for most FSHD2
patients by derepressing DUX4 transcription (26). DUX4
mRNA expression is so far the only molecular determinant in
common between FSHD1 and FSHD2 patients, which strongly
suggests its direct implication in the FSHD phenotype.
Despite the fact that DUX4-FL is always expressed in FSHD
myotubes, the consequence of this expression on muscle func-
tion is not yet clearly understood and the link between the
DUX4 expression and the development of FSHD is not well
established.
We had access to quadriceps and trapezius muscle biopsies
isolated from a 14-week FSHD1 fetus from which we established
primary muscle cultures and investigated whether some molecu-
lar hallmarks of the pathology were already present in fetal biop-
sies and muscle cultures derived from these biopsies. We
observed that DUX4-FL is expressed in the myogenic cells
derived from the two FSHD1 biopsies and interestingly, myo-
tubes derived from FSHD1 quadriceps express four times
more DUX4-FL than myotubes derived from FSHD1 trapezius.
Moreover, some genes downstream of DUX4-FL were specific-
ally activated in FSHD1 biopsies and not in controls, thus
showing that a molecular signature potentially leading to
FSHD1 phenotype is already present in the developing fetal
muscle. Finally, we observed that TRIM43 and MBD3L2,
which are already overexpressed in FSHD1 fetal quadriceps
muscle biopsies, are also expressed in adult quadriceps biopsies
at similar levels to those observed in FSHD1 fetal quadriceps
muscle biopsies, thus opening a new field of investigation con-
cerning the molecular mechanisms leading to FSHD.
RESULTS
DUX4-FL is expressed in cells isolated from fetal
FSHD1 muscles
As DUX4 has been described to be expressed in differentiated
cells, we used myotubes at day 5 of differentiation and compared
DUX4 mRNA expression in myoblasts derived from either fetal
FSHD1 trapezius (FTrap) or quadriceps (FQuad) and quadriceps
control cells (MCQ). Three primer sets were used (Fig. 1A):
DUX4-all primers are able to amplify all the DUX4 mRNA iso-
forms described previously (16), DUX4-FL primers can only
amplify the DUX4 long isoform where intron 1 is retained
(Fig. 1B) and DUX4-UTR primers are flanking the two introns
of DUX4 and can amplify both the DUX4-FL isoforms. When
DUX4-all primers were used, we observed that the total expres-
sion of the DUX4 isoform mRNAs was 5-fold lower in FTrap as
compared with FQuad myotubes (Fig. 1C). In the control myo-
tubes (MCQ), DUX4 was also observed but its expression was
10-fold less than that in FQuad. When specific primers to
DUX4-FL2 were used, we observed that the expression of
DUX4-FL2 was 3-fold lower in the FTrap than in the FQuad
(Fig. 1C) and DUX4-FL2 was never detected in control myo-
tubes (Fig. 1C and data not shown, performed on three other
control samples). Finally no amplification was observed in the
control cells with the DUX4-UTR primers whereas the two
DUX4-FL isoforms were observed in the FSHD fetal cells
(Fig. 1D).
These results show that both the DUX4-FL isoforms are
already expressed in muscle cells isolated from FSHD1 fetal bi-
opsies. This result was confirmed at the protein level: an immu-
nostaining against DUX4 was carried out on FQuad and revealed
that 8.89% of the nuclei within myotubes were DUX4 positive
(Fig. 1E).
FSHD fetal quadriceps and trapezius muscles have different
differentiation kinetics during development
In order to determine whether this differential DUX4 mRNA
expression could be owing to a difference in myotube formation,
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differentiation kinetics were analyzed. Cells were harvested at
different time points after differentiation and DUX4-all or
DUX4-FL2 mRNA were assessed by qPCR. For FQuad,
DUX4-all and DUX4-FL2 mRNA expression increased during
differentiation until day 4 and then decreased (Fig. 2A). For
FTrap, the expression pattern of DUX4-all mRNA was
delayed, with an increase until day 5–7 when a plateau was
observed (Fig. 2B). As previously observed, the expression
levels of DUX4-all and DUX4-FL were much higher (4–
5-fold) in FQuad as compared with FTrap independently of the
differentiation time point.
As we observed a delay in the expression of DUX4 mRNA in
FTrap as compared with FQuad, we investigated whether the
kinetics of differentiation/fusion were similar in both the cul-
tures. The expression of Myogenin (MyoG), a transcriptional
activator of the myogenic program that permits the transition
from proliferating myoblasts to differentiating myotubes (for
review see (27)), was compared between FQuad and FTrap
differentiated cultures. Interestingly, differences were observed:
in FQuad cultures, the peak of expression of MyoG mRNA was
observed at D1 of differentiation and then its expression
decreased (Fig. 3A). In FTrap cultures, the MyoG peak was
observed at D4, suggesting a delay in the activation of the
genes required for differentiation and thus of the whole differen-
tiation program. This delay in differentiation was confirmed
using the inclusion of BIN1 exon11 in BIN1 mRNA. Inclusion
of the exon 11 is specific of muscle differentiation, and this gen-
erates an isoform of BIN1 implicated in tubular invaginations of
the membrane (28). Exon 11 inclusion was clearly observed at
D1 for FQuad, whereas it was included only from D4 in FTrap
(Fig. 3B and C). These results strongly suggest that there is a
delay in the activation of the myogenic program in FTrap as com-
pared with FQuad.
We next investigated whether the differences we observed
between FQuad and FTrap are related to the pathology or to
an intrinsic difference between the different muscle groups
Figure 1.The expression of DUX4-FL mRNA in FSHD and control fetal myotubes. (A) Schematic representation of the DUX4 gene and the resulting DUX4 mRNA
expression in muscle. The two primer locations that have been used are represented. (B) Representation of the DUX4 mRNA isoforms previously described (16). The
primers for DUX4-all are able to amplify all of the DUX4 isoforms whereas the primers for DUX4-FL cannot amplify DUX4-s or DUX4-FL1. The PCR product sizes
are indicated. (C) DUX4 relative expression in fetal-derived FSHD1 (FQuad and FTrap) and control (MCQ) myotubes after 5 days of differentiation. A RT-qPCR
(taqman assay) was carried out on 1 mg of total RNA using either DUX4-all (black bars) or DUX4-FL (gray bars) primer sets. The results obtained with FQuad
were used as a reference (and arbitrarily put at 1) and were normalized using B2M. (D) The amplification products using the DUX4-UTR or B2M primers were sepa-
rated on a 2% agarose gel. The expected sizes of the PCR product were 368 bp when both introns 1 and 2 are spliced and 504 bp when intron 1 is retained. The molecular
weight is a 100 bp ladder. The exons of DUX4 are indicated as gray boxes numbered 1 to 3. I: Intron; gDNA: genomic DNA. (E) Immunostaining against DUX4 was
realized on FQuad 5 days after the induction of differentiation. On the upper panel, DUX4 was labeled with the E5.5 antibody (dilution 1/10). In the lower panel, nuclei
have been counterstained with Dapi. The percentage of DUX4-positive nuclei represents 8.89% of the total number of nuclei within myotubes.
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(quadriceps versus trapezius). The same experiments were per-
formed with cells isolated from fetal control biopsies (i.e.
without any neuromuscular disease). We searched for DUX4
mRNA expression during the kinetics of differentiation by
qPCR but never observed a consistent expression of DUX4-FL
mRNA although sporadically amplification could be detected,
thus confirming previous reports (17,29). As for the FSHD cul-
tures, we also observed in four control cultures a delay in
MyoG mRNA expression (Supplementary Material, Fig. S1),
thus confirming that the delay we had initially observed in the
FSHD1 fetal trapezius muscle is owing to an intrinsic difference
in muscle maturation between trapezius and quadriceps rather
than being directly linked to FSHD.
Genes downstream of DUX4-FL are activated in myotubes
derived from FTrap and FQuad
DUX4-FL overexpression in vitro potentially induces the ex-
pression of several genes (14,24). As DUX4-FL mRNA expres-
sion levels are different in FTrap and FQuad myotubes, we
investigated the expression of these DUX4-FL target genes in
cultures derived from FTrap and FQuad. The expression of
MBD3L2, ZSCAN4, TRIM43, DEFB103 and ZNF217
mRNAs was analyzed by qPCR. All of these genes, except
ZNF217, were activated during differentiation (Fig. 4A). It
should be noted that the kinetics of gene expression were differ-
ent during differentiation of cultures derived from FTrap and
FQuad: whereas the expression of target genes was maximal at
day 4 of differentiation in FQuad cultures, this peak was
delayed to day 5 to 7 in FTrap cultures, as observed for DUX4
mRNA expression. The relative expression levels of MBD3L2
and ZSCAN4 mRNA were next compared between FQuad and
FTrap cultures (Fig. 4B). We observed that the levels of
MBD3L2 and ZSCAN4 expression were 3–5-fold lower in
FTrap than in FQuad cultures, as was observed for DUX4
mRNA expression.
FQuad and FTrap myoblasts were next transduced using a len-
tiviral vector containing an shRNA against all DUX4 mRNA iso-
forms. In cells transduced with the DUX4 shRNA (Fig. 5A), a
down-regulation of DUX4-FL mRNA was observed (21 and
44% of residual mRNA in FQuad and FTrap myotubes, respect-
ively, at day 5 of differentiation), demonstrating the efficacy
of the shRNA. The depletion of DUX4 was also demonstrated
at the protein level using a DUX4-specific antibody (Supplemen-
tary Material, Fig. S2). We next investigated the expression level
of MBD3L2, ZSCAN4, DEFB103, TRIM43 and ZNF217 in the
transduced cells (Fig. 5B). In the cells transduced with the
empty shRNA, the mRNA expression level of the target genes
Figure 2.The expression of DUX4 mRNA in FTrap and FQuad during myotubes
formation. Differentiation kinetics was performed on FQuad and FTrap cultures.
Cells were harvested at different time points. Total RNA was extracted using
trizol, and RT-qPCRs using either Dux4-all (A) or DUX4-FL (B) primers were
performed. The results obtained with FQuad in proliferation were used as a ref-
erence and were normalized to B2M. The experiments were repeated in dupli-
cate. P: proliferation; D: day after the induction of differentiation. Error bars
represent SD of PCR triplicate.
Figure 3. Characterization of the differentiation kinetics in FQuad and FTrap.
To analyze differentiation kinetics on FQuad and FTrap, total RNA was extracted
at different time points after the induction of differentiation by serum starvation.
RT-qPCR was performed for the detection of MyoG (myogenin) (A) and BIN1
exon 11 (B FQuad; C FTrap). B2M was used as the normalizer.
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(except for DEFB013 in FQuad) increases during differentiation
as expected. As previously observed in Figure 4A, the
differentiation process did not modulate the expression level
of ZNF217, thus suggesting that ZNF217 expression is not regu-
lated by DUX4. This was confirmed in the cells transduced with
the shDUX4, where the mRNA expression level of ZNF217 was
not affected by the presence of the shRNA (Fig. 5B), whereas for
the other genes, the presence of the DUX4 shRNA inhibited their
overexpression during differentiation, thus confirming the
down-regulation of the DUX4 expression that turns down its
target genes. The levels of expression of DUX4-FL downstream
targets further confirm the different levels of DUX4 expression
observed in the differentiated cultures.
As many genes have previously been described to be modu-
lated by the overexpression of DUX4-FL, we investigated the
impact of the shDUX4 expression in FQuad and FTrap on the ex-
pression of TP53, THOC4, DBR1, TFiP11, SRSF8, PRAMEF1
and MURF1 (Supplementary Material, Fig. S3). None of
these genes were modulated except PRAMEF1, which was
dramatically down-regulated in both FQuad and FTrap when
the shDUX4 is expressed and MURF1 mRNA, which was
up-regulated.
Genes downstream of DUX4-FL are also specifically
activated in FSHD1 fetal biopsies
Broucquault et al. (29) have shown previously that DUX-FL is
expressed in fetal FSHD muscle biopsies and because we have
used the same FSHD biopsies as them we decided to investigate
the mRNA expression level of genes downstream of DUX4-FL.
Interestingly, we found that MBD3L2 and TRIM43 mRNA
expression levels were systematically higher in the fetal FSHD
biopsies (18–36-fold and 10–26-fold for MBD3L2 and
TRIM43, respectively), indicating that these DUX4-FL down-
stream genes are specifically activated in FSHD samples
(Fig. 6). However, DEFB103, ZSCAN4, PRAMEF1 and
ZNF217 mRNA expression levels were not different in FSHD
biopsies as compared with control biopsies. These results
Figure 4.The expression level of genes downstream of DUX4 in FQuad and FTrap. Real-time RT-PCRs were carried out at different time points after the induction of
differentiation. Several genes described as being activated by DUX4 were tested. The experiment was made on FQuad (black bars) and FTrap (gray bars). (A) Values
measured in each cell type were normalized to its level in proliferation condition. (B) The results are normalized to the level of expression in proliferatingFQuad. FTrap
expression level is thus relative to FQuad, which allows a better comparison between both differentiated cultures. Error bars represent SD of PCR triplicates carried out
on two independent kinetic experiments.
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demonstrate that a modification in the expression of some but not
all of the genes downstream of DUX4-FL is already present in
fetal FSHD1 biopsies, strongly suggesting that DUX4-FL is
also expressed during fetal development.
Expression of genes downstream of DUX4-FL
is similar in fetal and adult samples
We next investigated the mRNA expression levels of MBD3L2,
ZSCAN4, ZNF217, PRAMEF1, DEFB103 and TRIM43 in adult
FSHD and control biopsies (Fig. 7A). We did not see any differ-
ence for ZNF217 and DEFB103. The overexpression of
ZSCAN4 and PRAMEF1 was not confirmed in all adult
samples. Finally, we did observe a clear modification in
MBD3L2 and TRIM43 mRNA expression levels because the
means of mRNA overexpression were 63 and 163, respectively.
It should be noted that the FSHD1 samples are heterogeneous
with sample #FSH1 always showing an important activation of
the genes studied and sample #FSH3 always showing a very
low activation of these genes. As FSHD1 has not been described
to be a fetal pathology, we investigated whether the mRNA ex-
pression levels of TRIM43 and MBD3L2 were similar in adult
and fetal biopsies. As shown in Figure 7B, we observed that
the expression levels of both genes were comparable in fetal
and adult FSHD biopsies.
DISCUSSION
Recent studies have suggested that DUX4 is a central player in
FSHD pathophysiology. Indeed, the isoform DUX4-FL is
expressed in myotubes isolated not only from FSHD1 but also
from FSHD2 patients and has been shown to be toxic for myonu-
clei (14,16,20,26,30). Nevertheless, despite the fact that DUX4
might play an important role in the pathology, the mechanisms
by which DUX4 is involved in FSHD still needs to be deci-
phered. One key to understanding its action is to clearly define
when it first begins to be expressed in the skeletal muscle. Clin-
ical features of FSHD usually appear in the second decade of life.
However, a minority of patients carrying the most extended con-
traction develop the disease during late childhood. Nevertheless,
nothing is known about the possible effect the D4Z4 contraction
could have during fetal muscle growth and development.
In this article, we investigated the DUX4 expression during
fetal development and show that DUX4-FL mRNA is already
expressed in primary myogenic cells derived from two muscle
biopsies derived from a single FSHD1 fetus (owing to the diffi-
culty in obtaining FSHD fetal cells, our in vitro study was
restricted to 1 fetus). Interestingly, the percentage of nuclei
expressing the protein DUX4 does not seem to be different in
fetal and in adult myotubes: DUX4 is present in almost 9% of
the nuclei in fetal cells, and it was previously published that
between 0.5 and 10% of the nuclei are DUX4 positive in adult
Figure 5.DUX4 inhibition using shDUX4 in FQuad and FTrap and activation of genes downstream of DUX4. A lentivirus (pLL3.7) carrying both an shRNA directed
against DUX4 and a CMV-GFP cassette was used to transduce FQuad (left panel) or FTrap (right panel) cultures. After sorting of the CD56+ (a marker for myogenic
cells) and GFP+ double positive cells, a differentiation kinetic was carried out. (A) DUX4 mRNA expression was analyzed by real-time PCR using the DUX4-all
primers in the Fquad (left panel) and FTrap (right panel) transduced cells. At day 5 of differentiation, a student’s t-test reveals that P ¼ 0.04 and 0.03 for FQuad
and FTrap, respectively. (B) The mRNA expression level of the downstream target genes was assessed by real-time PCR on FQuad (upper panel) and FTrap
(lower panel) cultures transduced with either the shDUX4 (black bar) or the shEmpty (gray bar). A T-test realized at day 5 of differentiation reveals that P , 0.05
for MBD3L2, ZSCAN4, TRIM43 and DEFB103. Error bars represent SD of PCR triplicate realized on two independent experiments.
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cells (30,31). However, owing to the limited number of control
cells available for this study, we cannot speculate that
DUX4-FL is not expressed in fetal control cells as it was previ-
ously demonstrated with adult cells (17). Actually, Broucqsault
and colleagues (29) have observed a DUX4-FL mRNA expres-
sion in 8 of 27 fetal control biopsies. Several groups have previ-
ously shown that DUX4-FL mRNA is expressed in muscle
cells derived from adult FSHD1 muscle biopsies (12,14,16,
17,26,32), but this is the first time that the DUX4 expression
has been demonstrated in fetal FSHD1 cells. The two
DUX4-FL isoforms, in which the first intron is spliced or
not (DUX4-FL1 and DUX4-FL2, respectively), have been
described to be expressed in both adult FSHD1 and FSHD2 myo-
tubes, and we have confirmed this result on fetal FSHD1 myo-
tubes. Interestingly, independent of the DUX4 primer set that
was used, the DUX4 mRNA expression level was consistently
lower in the trapezius than that in the quadriceps. This last
result was surprising because the trapezius muscle is described
to be one of the first affected muscles and so we were expecting
to see a higher level of DUX4 mRNA in this muscle compared
with the quadriceps. Several possibilities could explain this
result: (i) as FSHD is a disease affecting muscles asymmetrically
by an unknown mechanism, it is possible that the biopsies were
realized on a future poorly affected trapezius and a highly
affected quadriceps and (ii) DUX4 expression is not the only de-
terminant that explains the pattern of the affected and non-
affected muscles in FSHD patients. This is in agreement with
the fact that DUX4-FL has also been described to be expressed
in control myotubes and biopsies (17,29). A third possibility is
that the DUX4 expression is more toxic in Trapezius than that
in Quadriceps owing to intrinsic difference between these two
muscles. When a myonucleus starts to express DUX4, this will
trigger apoptosis and cell death, thus decreasing the number of
DUX4-positive nuclei and global DUX4 mRNA expression in
FTrap, whereas FQuad myonuclei would not trigger apoptosis
in response to the DUX4 expression.
Recently, numerous target genes downstream of DUX4 have
been identified after transduction of control primary myoblasts
by a lentiviral vector expressing DUX4-FL (24). Similarly, of
the five genes we tested (MBD3L2, ZSCAN4, DEFB103,
Figure 6.The expression level of genes downstream of DUX4 in quadriceps fetal biopsies. Quadriceps biopsies from five FSHD1 fetuses (hatched bars) and 16 quad-
riceps control biopsies obtained at different stages of development (back bars) were analyzed. A RT-q PCR was made on each mRNA preparation to determine their
relative quantity. B2M was used as the normalizer gene. The result obtained with the Ctrl14 was used as the reference to generate arbitrary units in order to compare
results between samples. Statistical analyses (T-test) revealed that the mean expression level for MBD3L2 and TRIM43 was different in control and FSHD1 samples
(P ¼ 0.02 and 0.03, respectively).
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TRIM43 and ZNF217), all of them except ZNF217 were
up-regulated in the fetal cultures FQuad and FTrap during differ-
entiation. However, in fetal FSHD1 biopsies, we observed that
only MBD3L2 and TRIM43 were specifically up-regulated.
Considering that FSHD induces a muscle atrophy, which is
often asymmetric, it is possible that the modification of the
expression of the other genes (ZSCAN4, DEFB103 and
PRAMF1) in the FSHD fetal biopsies is influenced by this asym-
metry. Moreover, in adult FSHD1 biopsies, we also confirmed
that MBD3L2 and TRIM43 are up-regulated. These two genes
can therefore be considered as robust markers for the DUX4 ex-
pression in both fetal and adult samples. It should also be noted
that TRIM43 and MBD3L2 expression levels were similar in
fetal and adult FSHD1 biopsies. The molecular events leading
to the FSHD phenotype are thus already initiated during fetal de-
velopment. Because it is difficult to imagine that all five FSHD
fetuses would have been infantile cases, which represent
5–10% of all the FSHD cases, our data open a new field of
investigation for mechanisms leading to FSHD. Indeed, FSHD
is described as an adult onset myopathy with clinical signs of
the disease only appearing during the second decade of life.
One hypothesis is that muscle fibers can only tolerate a given
amount of DUX4 during a given amount of time, beyond
which the delicate balance of muscle maintenance and repair
will be lost. In this case, the amount of DUX4 expressed in
each fiber is the same throughout life but results in fiber
atrophy only after several years once the muscle is no longer
able to compensate for the toxic effect of DUX4. FSHD could
thus be at least partly attributed to the accumulation of DUX4
and genes downstream of DUX4 throughout life. An alternative
hypothesis would result from DUX4 acting already by some epi-
genetic mechanism during fetal skeletal muscle development
without having any major consequences on myogenesis and
fiber growth, until a secondary event potentiates its toxic effect.
In conclusion, our results demonstrate that DUX4-FL is
already expressed during fetal muscle development, as
Figure7.The expression level of genes downstream of DUX4 in quadriceps adult biopsies. (A) Four FSHD1 (hatched bars) and three healthy control (black bars) adult
quadriceps biopsies were analyzed. For each gene, the result obtained with the Ctrl1 was used as the reference for arbitrary quantification. B2M gene was used as
normalizer. Statistical analysis (Student’s T-test) reveals thatP, 0.05 only for MBD3L2 and TRIM43. (B) MBD3L2 and TRIM43 expression levels were compared
in five fetal (hatched bars) and four adult (black bars) FSHD1 biopsies. Statistical analysis (t-test) does not show any difference in adult and fetal samples (P ¼ 0.22 for
MBD3L2 and P ¼ 0.16 for TRIM43).
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evidenced in cultures derived from fetal biopsies, but more im-
portantly by the activation of DUX4 target genes in these
biopsies. Whether it is a priming event that requires additional
signals or the accumulation of this signal over time that triggers
the FSHD phenotype we do not know, and more research will be
needed before we understand the complexity of FSHD patho-
physiology.
MATERIALS AND METHODS
Ethic statement
This study and the collection of fetal and FSHD1 muscle biopsies
was approved by the ‘Agence Franc¸aise de la Biomedecine’ of
the Ministry of Health to have legal access to the biological ma-
terial in full accordance with the law (research protocol number
PFS12–007). Therapeutic abortions are following a very precise
protocol: after discussions with the medical team, the decision
can be made to terminate the pregnancy. The parents can then
choose to sign an informed consent for a fetal autopsy that will
be carried out by pathologists. If the parents indicate that they
accept that biological samples are taken for scientific investiga-
tions within the frame of scientific research on normal and patho-
logical prenatal development, muscle biopsies will be taken.
They will be used either to generate primary cultures of myo-
blasts or to be frozen for further molecular analyses.
FSHD patient reports
The FSHD1 fetuses were aborted for medical reasons. The fetal
muscle biopsies of FSH14.1 fetus were performed by fetopathol-
ogists at AP-HP (Assistance Publique—Hoˆpitaux de Paris). The
father was diagnosed for FSHD1 at age 23 and displayed a
typical clinical phenotype including facial and scapula fixator
muscle weakness. He carried four repeated units on 4qA
chromosome 4. He was 32 when the fetus, carrying the same con-
traction, was aborted and at present (2 years later), the father can
still walk but uses a cane. The genetic anomaly was inherited
from his father who carried the 4QA D4Z4 contraction. The
FSH14.2 fetus was aborted at 14 weeks of development and
carried 1.5 D4Z4 repeats. The FSH15 was aborted at 15 weeks
of development and carried four D4Z4 repeats. The fetuses
FSH22.1 and 22.2 were aborted at 24 weeks of development
and they both carried seven D4Z4 repeats.
Adult quadriceps muscle biopsies were obtained from typical
FSHD1 patients and healthy control individuals using standar-
dized muscle biopsy protocol. FSH1 and FSH2 were, respective-
ly, 59- and 60-year-old men carrying seven D4Z4 repeats with a
clinically non-affected quadriceps. FSH3 was a 62-year-old man
carrying seven D4Z4 repeats with clinically affected quadriceps
muscles. FSH4 was a 64-year-old woman carrying six D4Z4
repeats with mildly affected quadriceps. Healthy controls were
selected in the same age and sex range as the FSHD patients.
Muscle biopsies and cells
Primary cells from FSH14.1 quadriceps (FQuad) and trapezius
(FTrap) muscles were derived from the different muscle biopsies
coming from the same fetus. Briefly, the biopsies were carefully
minced, and the explants were plated in culture dishes previously
coated with FBS. Once the cells had migrated from the explants
to colonize the culture dish, they were trypsinized and the per-
centage of CD56-positive cells was determined by FACS ana-
lysis. Briefly, 50 000 cells were incubated with 1 ml of CD56
antibody (CD56-APC, Becton Dickinson, Le Pont de Claix,
France) in PBS FBS 2%. A FACSCalibur (Becton Dickinson,
Le Pont de Claix, France) was used to determine the myogeni-
city, i.e. percentage of CD56-positive cells. If this percentage
was lower than 80%, the myogenic cells were enriched in
CD56-positive cells using MACS columns according to the
manufacturer instructions (Miltenyi Biotec, Paris, France).
Cell culture
Fetal FSHD1 and control primary cells were cultivated in prolif-
eration medium (4 vol of DMEM, 1 vol of 199 medium, FBS
20%, Gentamycin at 50 mg/ml, Life technologies, Saint Aubin,
France). The differentiation was induced by replacing the prolif-
eration medium by DMEM supplemented with insulin (10 mg/
ml). The myogenicity, defined as the percentage of
CD56-positive cells, was checked before any experiments per-
formed with the cells, and the cells were always enriched in
CD56+ cells using MACS columns immediately before
plating if this percentage was ,80%.
Cell culture
After 5 days of differentiation, immunostaining was performed
using the E5.5 antibody, which recognizes the C-terminus part
of DUX4 (33). Cells were fixed with 4% paraformaldehyde for
10 min and permeabilized with 1% triton X-100 (Sigma) in
PBS for 10 min at room temperature. Blocking was realized
with PBS 2% FBS for 30 min at room temperature. DUX4 anti-
body (rabbit) was diluted 1/10 in PBS 2% FBS, and MF20
(Mouse IgG2B) was diluted 1/100. Cells were incubated over-
night with DUX4 alone or both antibodies and washed three
times with PBS 0.5% triton. Secondary antibodies were Ac
GAM IgG2B-488 for anti-MF20 and GAR IgG H + L-555 (1/
100) for DUX4. Incubation was carried out for 1 h in the dark.
Finally, nuclei were counterstained with Hoescht (1/1000,
Dako fluorescent mounting).
RNA extraction, PCR and real-time PCR
Total RNAs from either cells or human biopsies of muscles were
extracted using trizol according to the manufacturer’s protocol
(Life technologies, Saint Aubin, France). The quantity of RNA
was determined using a nanodrop ND-1000 spectrophotometer
(Thermo Scientific, Wilmington, DE, USA). The reverse tran-
scription (RT) was carried out on 1 mg of total RNA using the
Roche Transcriptor First Strand cDNA Synthesis Kit (Roche,
Meylan, France) at 608C for 50 min. In a final volume of
13 ml, 1 ml of oligo dT and 2 ml random hexameres were used
as RT primers. All of the primers used in this study are listed
in Table 1. With DUX4-UTR primers, the PCR was performed
in a final volume of 25 ml with 1 ml of RT product, 1 ml of
each forward and reverse primers at 20 pmol/ml. Thermal
cycling conditions were 948C for 5 min and then 36 cycles at
948C for 30 s and 628C for 45 s. The quantitative PCR was per-
formed in triplicate with the probe mastermix (Roche, Meylan,
France) on a LightCyclerw 480 Real-Time PCR System
(Roche, Meylan, France). DUX4 qPCR was performed in tripli-
cate. Each well contained 0.25 ml of RT product, 4.5 ml of the
probe mastermix 2X, 0.18 ml of each primers (20 pmol/ml) and
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0.18 ml of the DUX4 probe (10 pmol/ml) in a final volume of
9 ml. qPCR cycling conditions were as follows: 958C for
5 min, followed by 53 cycles at 958C for 30 s and 628C for
45 s. For the other genes, the qPCR was performed in a final
volume of 9 ml with 0.4 ml of RT product, 0.18 ml of each
forward and reverse primers 20 pmol/ml, and 4.5 ml of syber-
green mastermix 2X (Roche, Meylan, France). The qPCR
cycling conditions were 948C for 5 min, followed by 50 cycles
at 958C for 30 s and 608C for 15 s and 728C for 15 s.
To amplify BIN1, PCR was performed using 2X ReddyMix
PCR master mix (Thermo scientific, Rockford, IL, USA) with
1 ml of RT product, 0.5 ml of 20pmol/ml forward and reverse
primers, in a final volume of 25 ml. The cycling conditions
were as follows: 958C for 5 min, followed by 32 cycles at
958C for 20 s, 608C for 20 s and 728C for 20 s, then 728C for
7 min, on a thermocycler GeneAmp PCR System 2700
(Applied Biosystems, Saint Aubin, France).
DUX4 shRNA construct and transduction
The sequence of DUX4 was analyzed for siRNA target using the
Clontech software (http://bioinfo.clontech.com/rnaidesigner/
sirnaSequenceDesign.do). One siRNA was selected and synthe-
sized to be directly cloned into pLL3.7 (addgene, Plasmid
11795) using the hpaI and XhoI restriction enzyme sites. The oli-
gonucleotides were TGGCAAACCTGGATTAGAGTTTCAA
GAGAACTCTAATCCAGGTTTGCCTTTTTC for the sense
strand and TCGAGAAAAAGGCAAACCTGGATTAGAGTT
CTCTTGAAACTCTAATCCAGGTTTGCCA for the anti-
sense strand. The pLL3.7 shDUX4 vector was produced in
human embryonic kidney 293 cells by quadri-transfection of
plasmids encoding gag-pol proteins, Rev protein, envelop pro-
teins (VSVg) and the transgene using PEI. 48 and 72 h later;
the viral vector is filtered (0.22 mm) before being directly used
to transduce myoblasts.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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Table 1. Sequences of the primers
Targeted gene Primer Sequence Size (bp) Accession number
DUX4-all DUX4-all_fw CCCAGGTACCAGCAGACC 164 HQ266761
DUX4-all_rev TCCAGGAGATGTAACTCTAATCCA
DUX4-FL DUX4-FL_fw CCTGGGATTCCTGCCTTCTA 198 HQ266761
DUX4-FL_rev AGCCAGAATTTCACGGAAGA
DUX4-UTR DUX4-UTR_fw AGGCGCAACCTCTCCTAGAAAC 368 and 504 HQ266761
DUX4-UTR_rev TCCAGGAGATGTAACTCTAATCCA
Myogenin 820U19 GAGTTCAGCGCCAACCCAG 165 NM_002479.5
965L20 TGCCCGGCTTGGAAGACAAT
BIN1 BIN F AGAACCTCAATGATGTGCTGG 162 and 207 NM_139351.2
BIN R CGTGGTTGACTCTGATCTCGG
MBD3L2 MBD3L2_fw CGTTCACCTCTTTTCCAAGC 142 NM_144614.3
MBD3L2_rev AGTCTCATGGGGAGAGCAGA
ZSCAN4 ZSCAN4_fw GTGGCCACTGCAATGACAA 143 NM_152677.2
ZSCAN4_rev AGCTTCCTGTCCCTGCATGT
DEFB103 DEFB103_fw GAGGATCCATTATCTTCTGTTTGC 135 NM_018661.3
DEFB103_rev AGGCAGCTGAGCACAGCA
TRIM 43 TRIM43_fw ACCCATCACTGGACTGGTGT 100 NM_138800.1
TRIM43_rev CACATCCTCAAAGAGCCTGA
ZNF217 ZNF217_fw AAGCCCTATGGTGGCTCC 99 NM_006526.2
ZNF217_rev TTGATATGACACAGGCCTTTTTC
PRAMEF1 PRAMEF1_fw CTCCAAGGACGGTTAGTTGC 142 NM_023013.2
PRAMEF1_rev AGTTCTCCAAGGGGTTCTGG
TP53 TP53_fw GTTCCGAGAGCTGAATGAGG 159 NM_001126118.1
TP53_rev TCTGAGTCAGGCCCTTCTGT
MURF1 MURF1_fw CTTGACTGCCAAGCAACTCA 80 NM_032588.3
MURF1_rev CAAAGCCCTGCTCTGTCTTC
THOC4 THOC4_fw CAGCAGACGTGCACTTTGAG 107 NM_005782.3
THOC4_rev TGACGTGACAAGCTGAATGTT
DBR1 DBR1_fw AAACCATGAAGCCTCAAATCA 92 NM_016216.3
DBR1_rev TTACCACACCAGCCAAACCT
SRSF8 SRSF8_fw TTAGCTGGGCGCTGATTAGG 71 NM_032102.2
SRSF8_rev AATGAAGCCAGGTCCCGAAG
TFIP11 TFIP11_fw GCAGATGCCTTTCACAGGTT 95 NM_012143.2
TFIP11_rev ACCATCGGGTCACAGTTCC
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